No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 29 of the 29 quarters in the window, leaving 0 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 947.8x · 10Y median 971.0x · 25th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 30
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T15:07:09.039Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Immunovant, Inc. (IMVT) stock was $32.58 as of Oct 6, 2026, 11:05 AM EDT, down 2.01% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +96.1% · 3-year avg -3.2%/yr · 5-year avg +29.9%/yr
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions.
Biotechnology · Durham, NY
Next Earnings Date
Nov 9, 2026
34 days away
EPS Estimate
-0.73
Revenue Est.
$7.09M
Last Quarter Results
EPS
$-0.68
vs Estimate
$-0.61
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1IMVT | $6.72B | $32.58 | -2.01% | +96.11% | +29.93% | N/A | N/A |
| 2CHE | $6.67B | $510.50 | -0.16% | +15.83% | +3.58% | +14.19% | vs IMVT |
| 3HIMS | $6.61B | $29.62 | -0.17% | -43.37% | +32.23% | N/A | vs IMVT |
| 4LNTH | $6.52B | $100.20 | +0.01% | +85.57% | +31.73% | +28.40% | vs IMVT |
| 5AMRX | $6.50B | $20.36 | +0.05% | +95.23% | +30.25% | -1.73% | vs IMVT |
| 6ALKS | $7.03B | $41.89 | -2.03% | +37.46% | +6.73% | -0.82% | vs IMVT |
forward FY estimate
N/A
$7.09M
vs Estimate
$7.09M
Consensus Rating
Based on 16 analysts
Average Price Target
$48.88
+50.0% upside
Low
$30.00
Current
$32.58
High
$66.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.80 | $-0.74 | $-0.64 | 4 |
| Quarter ending Dec 2026 | $-0.81 | $-0.73 | $-0.63 | 4 |
| Quarter ending Mar 2027 | $-0.73 | $-0.73 | $-0.73 | 1 |
| Quarter ending Jun 2027 | $-0.73 | $-0.73 | $-0.73 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $-3.13 | $-2.94 | $-2.63 | 9 |
| FY 2028 | $-3.37 | $-2.92 | $-2.51 | 8 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $7.09M | $7.09M | $7.09M | 1 |
| Quarter ending Dec 2026 | $7.09M | $7.09M | $7.09M | 1 |
| Quarter ending Mar 2027 | $14.40M | $14.40M | $14.40M | 1 |
| Quarter ending Jun 2027 | $7.09M | $7.09M | $7.09M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2027 | $6.64M | $6.64M | $6.64M | 9 |
| FY 2028 | $42.94M | $42.94M | $42.94M | 9 |
